Answers are grounded in this paper and cite their sources.
Clinical and pharmacokinetic analysis reports hepatotoxicity risk from sotorasib following immunotherapy in non-small cell lung cancer, highlighting potential drug interactions.
Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, sotorasib concentrations, and the incidence of hepatotoxicity during sotorasib.
No takes yet. Share an insight, caveat, or question.
Ernst et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: